Physician in the Loop: Endocrinology https://physicianintheloop.org/specialties/endocrinology/ Transistor (https://transistor.fm) https://feeds.transistor.fm/physician-in-the-loop-endocrinology The week's innovation news in endocrinology for endocrinologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. From the Specialties pages of Physician in the Loop, where every story links to its sources: physicianintheloop.org/specialties/endocrinology/. Read by AI voices. Nomad Medical Group, PLLC dcd8aa2b-d2ee-5802-99e4-c66ccccfbcf0 yes en Sun, 08 Nov 2026 12:39:21 -0700 Sun, 08 Nov 2026 12:40:02 -0700 https://img.transistorcdn.com/L5YoSZNvzuYI7fSmrl9Ea9FCfO59DtBQ6Dw_XKpcw5c/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85MmJk/MmQyZjBiMDUwYTBh/Y2I5NWVjNzcyNGEy/MjI0YS5qcGc.jpg Physician in the Loop: Endocrinology https://physicianintheloop.org/specialties/endocrinology/ episodic Nomad Medical The week's innovation news in endocrinology for endocrinologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. From the Specialties pages of Physician in the Loop, where every story links to its sources: physicianintheloop.org/specialties/endocrinology/. Read by AI voices. The week's innovation news in endocrinology for endocrinologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. endocrinology, endocrinology news, innovation, medicine, physicians, AI in medicine, weekly briefing Ryan Gillum No No Weekly Briefing for November 1 to 7, 2026 5 5 Weekly Briefing for November 1 to 7, 2026 full dbe26be8-b363-4eb7-8f4e-c77d6f10137a https://share.transistor.fm/s/48f3c4f8 A systolic target below 120 mm Hg did not significantly reduce cardiovascular events in 9,476 adults with type 2 diabetes in OPTIMAL-DIABETES, reported Nov. 7 at the American Heart Association (AHA) Scientific Sessions. The Centers for Medicare & Medicaid Services (CMS) finalized the 2027 physician fee schedule with new remote monitoring rules, and an AHA abstract found no rise in cardiovascular events with hormone therapy started at ages 45 to 59.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-11-01/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> A systolic target below 120 mm Hg did not significantly reduce cardiovascular events in 9,476 adults with type 2 diabetes in OPTIMAL-DIABETES, reported Nov. 7 at the American Heart Association (AHA) Scientific Sessions. The Centers for Medicare & Medicaid Services (CMS) finalized the 2027 physician fee schedule with new remote monitoring rules, and an AHA abstract found no rise in cardiovascular events with hormone therapy started at ages 45 to 59.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-11-01/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 08 Nov 2026 12:39:21 -0700 Nomad Medical Nomad Medical 213 Intensive blood pressure target fails to cut events in type 2 diabetes; CMS finalizes 2027 fee schedule; hormone therapy shows no cardiovascular harm Intensive blood pressure target fails to cut events in type 2 diabetes; CMS finalizes 2027 fee schedule; hormone therapy shows no cardiovascular harm Endocrinology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 25 to 31, 2026 4 4 Weekly Briefing for October 25 to 31, 2026 full d1609565-d88a-4612-a883-b1d846ca1dce https://share.transistor.fm/s/cbca0089 Eli Lilly said retatrutide lowered A1C more than semaglutide 2 mg and more than doubled its weight loss in a phase 3 type 2 diabetes trial. The Food and Drug Administration removed breast cancer, cardiovascular and dementia statements from boxed warnings on three estradiol patches, and Vanda Pharmaceuticals reported phase 3 data on tradipitant for semaglutide-induced vomiting.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-10-25/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Eli Lilly said retatrutide lowered A1C more than semaglutide 2 mg and more than doubled its weight loss in a phase 3 type 2 diabetes trial. The Food and Drug Administration removed breast cancer, cardiovascular and dementia statements from boxed warnings on three estradiol patches, and Vanda Pharmaceuticals reported phase 3 data on tradipitant for semaglutide-induced vomiting.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-10-25/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 01 Nov 2026 04:07:51 -0700 Nomad Medical Nomad Medical 183 Retatrutide tops semaglutide on A1C and weight in type 2 diabetes, Lilly says; FDA trims boxed warnings on three estradiol patches Retatrutide tops semaglutide on A1C and weight in type 2 diabetes, Lilly says; FDA trims boxed warnings on three estradiol patches Endocrinology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 11 to 17, 2026 3 3 Weekly Briefing for October 11 to 17, 2026 full ed960a0b-e8fc-4a4f-95ec-2c609de008e4 https://share.transistor.fm/s/aeabbdff Sequel said Oct. 16 that the Food and Drug Administration (FDA) cleared its twiist automated insulin delivery system for adults with insulin-treated type 2 diabetes.

In a randomized trial in 24 Tanzanian hospitals, 35.9% of people with referable diabetic retinopathy attended an eye clinic within eight weeks after AI-supported screening, versus 18.2% with standard screening, and a Nature Medicine study of 8,127 women in a digital-first GLP-1 program reported 15.5% mean weight loss.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-10-11/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sequel said Oct. 16 that the Food and Drug Administration (FDA) cleared its twiist automated insulin delivery system for adults with insulin-treated type 2 diabetes.

In a randomized trial in 24 Tanzanian hospitals, 35.9% of people with referable diabetic retinopathy attended an eye clinic within eight weeks after AI-supported screening, versus 18.2% with standard screening, and a Nature Medicine study of 8,127 women in a digital-first GLP-1 program reported 15.5% mean weight loss.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-10-11/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 18 Oct 2026 09:06:47 -0600 Nomad Medical Nomad Medical 221 FDA clears automated insulin delivery in type 2 diabetes; AI lifts retinopathy follow-up in Tanzania; digital GLP-1 program reports 15.5% loss FDA clears automated insulin delivery in type 2 diabetes; AI lifts retinopathy follow-up in Tanzania; digital GLP-1 program reports 15.5% loss Endocrinology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 5 to 11, 2026 2 2 Weekly Briefing for October 5 to 11, 2026 full 9f5ca242-ed48-4a6a-97b6-39af4dd1ba79 https://share.transistor.fm/s/21edfe37 A deep learning model that screens chest radiographs for osteoporosis reached an area under the curve of 0.88 to 0.93 in three external validation cohorts, Korean researchers reported in npj Digital Medicine. A Chinese group reported a large language model system for hyperthyroidism admission notes with a 6.67% hallucination rate, versus 26.67% for a general large language model.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-10-05/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> A deep learning model that screens chest radiographs for osteoporosis reached an area under the curve of 0.88 to 0.93 in three external validation cohorts, Korean researchers reported in npj Digital Medicine. A Chinese group reported a large language model system for hyperthyroidism admission notes with a 6.67% hallucination rate, versus 26.67% for a general large language model.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-10-05/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Mon, 12 Oct 2026 03:49:10 -0600 Nomad Medical Nomad Medical 144 AI reading chest X-rays flags osteoporosis in external cohorts; LLM system refines hyperthyroidism admission notes AI reading chest X-rays flags osteoporosis in external cohorts; LLM system refines hyperthyroidism admission notes Endocrinology,physicians,medical news,weekly briefing No Weekly Briefing for September 28 to October 4, 2026 1 1 Weekly Briefing for September 28 to October 4, 2026 full 00438600-9fb5-4d98-96e8-9161d7f5ff1d https://share.transistor.fm/s/d3771ba1 Eli Lilly reported phase 3 results for retatrutide and orforglipron at the European Association for the Study of Diabetes (EASD) meeting in Milan, with both trials published simultaneously in The Lancet. The Food and Drug Administration (FDA) approved tiratricol as the first treatment for MCT8 deficiency, and Lilly said a phase 2b combination of eloralintide and tirzepatide produced up to 23.3% weight loss.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-09-28/

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Eli Lilly reported phase 3 results for retatrutide and orforglipron at the European Association for the Study of Diabetes (EASD) meeting in Milan, with both trials published simultaneously in The Lancet. The Food and Drug Administration (FDA) approved tiratricol as the first treatment for MCT8 deficiency, and Lilly said a phase 2b combination of eloralintide and tirzepatide produced up to 23.3% weight loss.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/endocrinology/2026-09-28/

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Mon, 05 Oct 2026 21:31:37 -0600 Nomad Medical Nomad Medical 233 Retatrutide yields 18.8% weight loss in type 2 diabetes; orforglipron meets cardiovascular safety goal; FDA approves tiratricol Retatrutide yields 18.8% weight loss in type 2 diabetes; orforglipron meets cardiovascular safety goal; FDA approves tiratricol Endocrinology,physicians,medical news,weekly briefing No